Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23627230 | 0.92 | PARP11 (0.58) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL18500475 | 0.89 | PARP10 (0.58) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL18713799 | 0.88 | PARP11 (0.62) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL16561672 | 0.80 | PARP10 (0.76) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL8155722 | 0.78 | PARP11 (1.00) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL8167145 | 0.77 | PARP10 (0.76) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL8155744 | 0.77 | PARP10 (0.74) | PARP11PARP10GSK3BPARP1PDPK1 | |
| SCHEMBL28140768 | 0.77 | PARP11 (0.74) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL8155836 | 0.77 | PARP10 (0.76) | PARP11PARP10GSK3BGRM5PARP1 | |
| SCHEMBL8161680 | 0.76 | PARP11 (0.68) | PARP11PARP10GSK3BGRM5PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PARP11 685/4885PARP10 1776/4885GSK3B 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.